Eli Lilly: positive results for tirzepatide

(CercleFinance.com) - Eli Lilly announced this weekend that results from a Phase III study showed that tirzepatide 'significantly' reduced the risk of worsening heart failure-related events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.


Specifically, the drug reduced the risk of hospitalisation for heart failure by 56% and improved symptoms and physical limitations.

Treated patients also improved their exercise capacity, walking 38.2 metres more in six minutes, and reduced their body weight by 15.7%, compared with 2.2% for placebo.

The steering committee, said that these results offer significant perspectives for the management of patients with HFpEF and obesity.


Copyright (c) 2024 CercleFinance.com. All rights reserved.